Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

[Delegation of GP services to medical assistants: Perspectives over time. Results from focus groups with medical assistants and GPs at 12-year intervals].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2026
Same journal

[Core competencies of physiotherapists for direct access of patients with musculoskeletal disorders in the German healthcare system - A Delphi survey].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2026
Same journal

[Reducing prescription errors in oncological systemic therapies by implementing software-assisted therapy planning].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2026
Same journal

[Supportive care needs in patients with incurable cancer: Results of an integrative data analysis].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2026
Same journal

["Bringing one's own unique perspective into research" - Participants' experiences and perceptions regarding the implementation of a citizen advisory board in general practice research].

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2026
Same journal

Developing a non-pharmacological pain management toolkit in nursing homes using a structured evidence-generation approach.

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

[Research in the pharmaceutical industry cannot be objective].

Wolfgang Becker-Brüser1

  • 1arznei-telegramm, A.T.I. Arzneimittelinformation Berlin GmbH, Bergstr. 38 A, Wasserturm, 12169 Berlin. redaktion@arznei-telegramm.de

Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen
|July 9, 2010
PubMed
Summary
This summary is machine-generated.

Pharmaceutical industry funding significantly biases clinical trial results, making it difficult to assess drug safety and efficacy. This bias impacts research, guidelines, and patient care, potentially leading to treatment errors.

More Related Videos

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
08:29

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion

Published on: March 31, 2022

Related Experiment Videos

Last Updated: Jun 11, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
08:29

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion

Published on: March 31, 2022

Area of Science:

  • Medical research methodology
  • Pharmaceutical industry influence
  • Clinical trial integrity

Context:

  • Increasing pharmaceutical industry funding for clinical studies.
  • Shift of trial conduct to contract research organizations.
  • Company interests driving research priorities.

Purpose:

  • To investigate the impact of pharmaceutical industry sponsorship on clinical trial outcomes.
  • To identify factors contributing to biased research results.
  • To assess the consequences of biased research on medical knowledge.

Summary:

  • Company-funded trials are four times more likely to favor the trial drug compared to other sponsors.
  • Bias can stem from study design (design bias), data manipulation, and non-publication (publication bias).
  • Reliable assessment of drug benefit and harm is compromised by biased published trials.

Impact:

  • Undermines the reliability of meta-analyses, clinical guidelines, and patient information.
  • Potential for widespread treatment errors due to skewed medical evidence.
  • Challenges the objectivity of medical research and drug evaluation.